This clinical trial focuses on triple negative breast cancer that has spread to other parts of the body (metastatic breast cancer). The study compares different treatment combinations to find the most effective approach for patients. The treatments being tested include chemotherapy drugs (carboplatin, cyclophosphamide, and paclitaxel) along with newer medicines called atezolizumab and bevacizumab, which help the immune system fight cancer cells.
The main purpose of the study is to determine which combination of treatments works best for different groups of patients based on specific characteristics of their cancer, particularly something called the BRCA1-like status. The study will also look at how well the treatments work when combined with atezolizumab, a type of immunotherapy that helps the body’s immune system attack cancer cells.
During the study, patients will receive their assigned treatment through an intravenous infusion. The medications will be given in different combinations, and doctors will monitor how well the treatments work in stopping or slowing down the growth of cancer. They will also track how long patients live without their cancer getting worse and examine various biological markers that might help predict which patients will respond best to specific treatments.
The Netherlands 
